SCHEMBL4120353

SCHEMBL4120353

CN(C)CCCN(CCCNC(=O)OC(C)(C)C)C(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ UTS2R Q9UKP6 2/20 0.42
▸ MTOR P42345 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ SIRT2 Q8IXJ6 1/20 0.40
▸ SIRT1 Q96EB6 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ MCHR1 Q99705 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ TMEM97 Q5BJF2 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ CACNA1B Q00975 2/20 0.39
▸ CACNA1H O95180 1/20 0.39
▸ EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4119975 0.96 UTS2R (0.42) CA1CA2UTS2RMTORMEN1
SCHEMBL4119233 0.89 UTS2R (0.46) CA1CA2UTS2RMTORMEN1
SCHEMBL4123918 0.86 MEN1 (0.57) CA1CA2UTS2RMTORMEN1
SCHEMBL4120374 0.86 MCHR1 (0.53) CA1CA2MTORMEN1KMT2A
SCHEMBL4124390 0.81 MCHR1 (0.54) CA1CA2MTORMEN1KMT2A
SCHEMBL4116418 0.81 MEN1 (0.52) UTS2RMTORMEN1KMT2AHTT
SCHEMBL4125813 0.80 GHSR (0.46) CA1CA2UTS2RMTORMEN1
SCHEMBL4129069 0.80 DRD2 (0.45) SIGMAR1MAPTEPHX2
SCHEMBL4114315 0.78 EPHX2 (0.50) MAPTEPHX2
SCHEMBL4119609 0.78 MEN1 (0.53) UTS2RMTORMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US disclosed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP disclosed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118330-A1 Diurea derivatives IL2, CASP2, MAVS CA1 4022/4885CA2 1456/4885UTS2R 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback